切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2012, Vol. 08 ›› Issue (06) : 787 -791. doi: 10.3877/cma.j.issn.1673-5250.2012.06.032

所属专题: 文献

综述

乳腺癌相关治疗导致妇科并发症的研究进展
曾俐琴1,*,*(), 王颀2, 孙小丽1, 罗喜平1   
  1. 1. 510010 广州,广东省妇幼保健院妇科
    2. 510010 广州,广东省妇幼保健院乳腺外科
  • 收稿日期:2012-09-01 修回日期:2011-11-01 出版日期:2012-12-01
  • 通信作者: 曾俐琴

Updated Progress of Gynecologic Complications in Breast Cancer With Adjuvant Therapy

Li-qin ZENG1(), Qi WANG2, Xiao-li SUN1, Xi-ping LUO1   

  1. 1. Department of Gynecology and Breast Surgery, Guangdong Women and Children Hospital, Guangzhou 510010, Guangdong Province, China
  • Received:2012-09-01 Revised:2011-11-01 Published:2012-12-01
  • Corresponding author: Li-qin ZENG
  • About author:
    (Corresponding author: ZENG Li-qin, Email: )
引用本文:

曾俐琴, 王颀, 孙小丽, 罗喜平. 乳腺癌相关治疗导致妇科并发症的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2012, 08(06): 787-791.

Li-qin ZENG, Qi WANG, Xiao-li SUN, Xi-ping LUO. Updated Progress of Gynecologic Complications in Breast Cancer With Adjuvant Therapy[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2012, 08(06): 787-791.

女性乳腺癌患者的相关治疗包括三苯氧胺(TAM)辅助内分泌治疗、术后化疗、去势治疗及激素替代治疗(HRT)等,可导致个体生殖器官,尤其是子宫内膜发生多种病理改变,临床应予以重视。TAM辅助化疗可能引起年轻女性乳腺癌患者卵巢储备功能下降,甚至闭经,应及时发现并采取相关干预措施。本研究聚焦女性乳腺癌患者相关术后治疗所致的妇科并发症及其临床监测、干预,包括其避孕、生育及哺乳等相关问题的研究进展。

Adjuvant therapy including endocrine therapy, chemotherapy, prophylactic castration, hormone replacement therapy(HRT) of breast cancer in women frequently causes episodes of reproductive organs, which could be associated with proliferative changes of the endometrium, or even endometrial cancer. Chemotherapy for breast cancer is likely to negatively impact on ovarian function. A number of surveillances and interventions should be done. And we reviewed updated progress of gynecologic complications in breast cancer with adjuvant therapy, including contraception, preservation of infertility, breastfeeding following breast cancer.

[1]
Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008[J]. 2007-11-01].

URL    
[2]
Pagani O, Goldhirsch A. Breast cancer in young women: Climbing for progress in care and knowledge[J]. J Clin Oncol, 2006, 2(5):717-732.
[3]
Lhomme C, Pautier P, Zagame L, et al. Surveillance de l'endomètredes femmessous tamoxifène endometrial surveillance of women on tamoxifen[J]. Gynécol Obstét Fertil, 2003, 31(7-8):647-656.
[4]
Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials[J]. Lancet, 1998, 351:1451-1467.
[5]
Luo YF, Liu YH. Effect on endometrial by tamoxifen[J]. J Reprod Med, 2004, 13(6):338-341.
[6]
Wang C, Wang C, Huang H, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. CA A Cancer J Clin, 2002, 94(8):2192-2198.
[7]
Wen ZQ, Wang QX, Leng QG, et al. Clinical and pathological observations of oral norethisterone treatment of endometrial hyperplasia with menorrhagia[J].Progr Obstet Gynecol, 1999, 8(1):44-46.
[8]
Rose P, Brandewie E, Abdul-Karim F. Failure of megestrol acetate to reverse tamoxifen induced endometrial neoplasia: Two case reports[J]. Int J Gynecol Cancer, 1999, 9(5):362-364.
[9]
Montz F, Bristow R, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol, 2002, 186(4):651-657.
[10]
Gardner F, Konje J, Abrams K, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial[J]. Lancet, 2000, 356(9243):1711-1717.
[11]
Chan S, Tam W, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG[J].Int J Obstet Gynaecol, 2007, 114(12):1510-1515.
[12]
Gardner F, Konje J, Bell S, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial[J]. Gynecol Oncol, 2009, 114(3):452-456.
[13]
Chin J, Konje J, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Datab Syst Rev (Online), 2009, 4:20-23.
[14]
Wang S, Zha XM. Effect of tamoxifen on uterus and ovaries of postmenopausal breast cancer patients[J].Acta Univ Med Nanjing, 2001, 21(4):320-321.
[15]
Ji XQ, Sun GZ.Clinical analysis of ovarian cysts cause by tamoxifen treatment for breast cancer[J]. Clin Med China, 2003, 19(7):660-661.
[16]
Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: Reproductive and late health effects of treatment[J]. J Clin Oncol, 2003, 21(22):4184-4193.
[17]
Sun ZY, Shen K, Lang JH, et al. Effect on ovarian function in ovarian cancer patients after chemotherapy of preserve fertility function surgery[J]. Acta Acad Med Sin, 2003, 25(4):431-433.
[18]
Kil WJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast cancer research and treatment[J].Breast Cancer Res Treat, 2006, 96(3):245-250.
[19]
Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer[J]. Cancer Control, 2002, 9(6):466-472.
[20]
Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy[J]. Cur Opin Obstet Gynecol, 2005, 17(1):21-26.
[21]
Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a[J]. JNCI Monographs, 2005, 2005(34):40-43.
[22]
Gwyn K. Children exposed to chemotherapy in utero[J]. JNCI Monographs, 2005, 2005(34):69-71.
[23]
Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer[J]. Breast Cancer Res, 2007, 9(6):115.
[24]
Pritchard KI. Endocrine therapy of advanced disease[J]. Clin Cancer Res, 2003, 9(1):460-467.
[25]
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: Trial stopped[J]. Lancet, 2004, 363(9407):453-455.
[26]
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Nation Cancer Instit, 2005, 97(7):533-535.
[27]
Sestak I, Kealy R, Edwards R, et al. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms[J]. J Clin Oncol, 2006, 24(24):3991-3996.
[28]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial[J]. JAMA: J Am Med Assoc, 2002, 288(3):321-333.
[29]
Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Nation Cancer Instit, 2008, 100(7):475-482.
[30]
Madalinska JB, van Beurden M, Bleiker E, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy[J]. J Clin Oncol, 2006, 24(22):3576-3582.
[31]
Chiarelli AM, Kirsh VA, Klar NS, et al. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection[J]. Cancer Epidemiol Biomark Prevent, 2006, 15(10):1856-1862.
[32]
Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review[J]. Clin Therapeut, 2007, 29(2):230-241.
[33]
Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001[J]. Eur J Cancer, 2005, 41(10):1446-1452.
[34]
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer[J]. BMC cancer, 2006, 6(1):194.
[35]
Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer[J]. J Clin Oncol, 2004, 22(20):4174-4183.
[36]
Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women[J]. J Am College Surgeons, 2008, 206(6):1193-1203.
[37]
Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: Population based study[J]. BMJ, 2007, 334(7586):194.
[38]
Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence[J]. Cancer, 2004, 100(3):465-469.
[39]
Avilés A, Neri N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero[J]. Clin Lymphom, Myelom Leukem, 2001, 2(3):173-177.
[40]
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5):283-291.
[41]
Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma[J]. Cancer, 1999, 85(11):2424-2432.
[42]
Trinh XB, Tjalma WAA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril, 2008, 90(1):17-22.
[43]
Helewa MLP, Provencher D, Lea R, et al. Breast cancer, pregnancy, and breastfeeding[J]. J Obstet Gynaecol Canada, 2002, 24(2):164-180.
[44]
Sacchini V, Pinotti JA, Barros ACSD, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem[J]? J Am College Surgeons, 2006, 203(5):704-714.
[1] 邵华, 那子悦, 荆慧, 李博, 王秋程, 程文. 术前经皮超声造影对乳腺癌腋窝前哨淋巴结转移及负荷的诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 849-853.
[2] 张旭, 徐建平, 苏冬明, 王彩芬, 王大力, 张文智. 男性乳腺肿块的超声造影特征[J]. 中华医学超声杂志(电子版), 2023, 20(08): 854-859.
[3] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[4] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[5] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[6] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[7] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[8] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[9] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[10] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[11] 汪洋, 李志鹏, 王可兵. 上尿路尿路上皮癌术后预防性膀胱灌注化疗的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 649-652.
[12] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[13] 李斌奎. 不可切除肝内胆管细胞癌的转化治疗[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 511-516.
[14] 刘飞, 王影新, 马骍, 辛灵, 程元甲, 刘倩, 王悦, 张军军. 不同介质腔内心电图定位技术在乳腺癌上臂输液港植入术中应用的随机对照研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 760-764.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要